Abstract
Although most of the symptoms of Parkinson’s disease (PD) seem to be motor-based, the non-motor symptoms (NMSs) of PD, often overshadowed, also constitute a major clinical challenge. The NMSs of PD, including neuropsychiatric, cognitive, gastrointestinal and sensory, not only are observed in later stages but also predominate in the early stages of PD. Research suggests that NMSs are present at onset, while some can precede the motor symptoms, often by many years [1–3]. The identification of premotor stages is based on the early detection of the combination of NMSs with PD detection: for example, olfactory changes are the most common NMS presenting in the early stages of PD and occur in 90 % of the patients [4, 5].
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Shiba M, Bower JH, Maraganore DM, et al. Anxiety disorders and depressive disorders preceding Parkinson’s disease: a case-control study. Mov Disord 2000;15:669-677.
Iranzo A, Molinuevo JL, Santamaria J, et al. Rapid-eye-movement sleep behavior disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 2006;5:572-577.
Antonini A. Non-motor symptoms in Parkinson’s disease. Eur Neurol Rev 2009;4:25-27.
Mueller A, Abolmaali ND, Hakimi AR, et al. Olfactory bulb volumes in patients with idiopathic Parkinson’s disease a pilot study. J Neural Transm 2005;112:1363-1370.
Berendse HW. I. 4 Early diagnosis in PD: olfaction. Parkinsonism Rel Disord 2006;12:1-2.
Miyasaki JM, Shannon K, Voon V, et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:996-1002.
Forjaz MJ, Frades-Payo B, Martinez-Martin P. [The current state of the art concerning quality of life in Parkinson’s disease: II. Determining and associated factors.] Rev Neurol 2009;49:655-660.
Frades-Payo B, Forjaz MJ, Martinez-Martin P. [The current state of the art concerning quality of life in Parkinson’s disease: I. Instruments, comparative studies and treatments]. Rev Neurol 2009;49:594-598.
Chaudhuri KR, Martinez-Martin P. Quantitation of non-motor symptoms in Parkinson’s disease. Eur J Neurol 2008;15(suppl 2):2-7.
Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord 2006;21:916-923.
Martinez-Martin P, Schapira AH, Stocchi F, et al. Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 2007;22:1623-1629.
Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, et al. The nondeclaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord 2010;25:697-701.
Wang G, Wan Y, Cheng Q, et al. Malnutrition and associated factors in Chinese patients with Parkinson’s disease: Results from a pilot investigation. Parkinsonism Relat Disord 2010;16:119-123.
Cervantes-Arriaga A, Rodriguez-Violante M, Villar-Velarde A, Lopez-Gomez M, Corona T. [Metric properties of clinimetric indexes for non-motor dysfunction of Parkinson’s disease in Mexican population.] Rev Invest Clin 2010;62:8-14.
Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: Results from an international pilot study. Mov Disord 2007;22:1901-1911.
Honig H, Antonini A, Martinez-Martin P, et al. Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009;24:1468-1474.
Kim HJ, Park SY, Cho YJ, et al. Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment. J Neurol Sci 2009;287:200-204.
Martinez-Martin P, Rodriguez-Blazquez C, Abe K, et al. International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease. Neurology 2009;73:1584-1591.
Wang G, Hong Z, Cheng Q, et al. Validation of the Chinese Non-Motor Symptoms Scale for Parkinson’s disease: Results from a Chinese pilot study. Clin Neurol Neurosurgery 2009;111:523-526.
Barone P, Antonini A, Colosimo C, et al. The PRIA MO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 2009;24:1641-1649.
Colosimo C, Morgante L, Antonini A, et al. Non-motor symptoms in atypical and secondary parkinsonism: the PRIA MO study. J Neurol 2010;257:5-14.
Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
Global Parkinson’s Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov Disord 2002;17:60-67.
Lohle M, Storch A, Reichmann H. Beyond tremor and rigidity: non-motor features of Parkinson’s disease. J Neural Transm 2009;116:1483-1492.
Wolters EC. Non-motor extranigral signs and symptoms in Parkinson’s disease. Parkinsonism Relat Disord 2009;15(suppl 3):S6-S12.
Qin Z, Zhang L, Sun F, et al. Health related quality of life in early Parkinson’s disease: Impact of motor and non-motor symptoms, results from Chinese levodopa exposed cohort. Parkinsonism. Rel Disord 2009;15:767-771.
Chaudhuri KR, Healy, DG, Schapira AH. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol 2006;5:235-245.
Miller E, Berrios GE, Politynska BE. Caring for someone with Parkinson’s disease: factors that contribute to distress. Int J Geriatr Psychiatry 1998;11:263-268.
Carter JH, Stewart BJ, Archbold PG, et al. Living with a person who has Parkinson’s disease: the spouse’s perspective by stage of disease. Mov Disord 2004;13:20-28.
Meara J, Mitchelmore E, Hobson P. Use of the GDS-15 geriatric depression scale as a screening instrument for depressive symptomatology in patients with Parkinson’s disease and their carers in the community. Age Aging 1999;28:35-38.
Habermann B. Spousal perspective of Parkinson’s disease in middle life. J Adv Nurs 2000;31:1409-1415.
Fernandez HH, Tabamo REJ, David RR, Friedman JH. Predictors of depressive symptoms among spouse caregivers in Parkinson’s disease. Mov Disord 2001;16:1123-1125.
Caap-Ahlgren M, Dehlin O. Factors of importance to the caregiver burden experienced by family caregivers of Parkinson’s disease patients. Aging Clin Exp Res 2002;14:371-377.
Edwards NE, Scheetz PS. Predictors of burden for caregivers of patients with Parkinson’s disease. J Neurosci Nurs 2002;34:184-190.
Happe S, Berger K. The association between caregiver burden and sleep disturbances in partners of patients with Parkinson’s disease. Age Ageing 2002;31:349-354.
Thommessen B, Aarsland D, Braekhus A, Oksengaard AR, Engedal K, Laake K. The psychosocial burden on spouses of the elderly with stroke, dementia and Parkinson’s disease. Int J Geriatr Psychiatry 2002;17:78-84.
Martinez-Martin P, Guerrero-Diaz MT, Frades-Payo B. [Neuropsychological disorders in Parkinson’s disease: evaluating them and their impact on the caregiver]. Rev Neurol 2004;39:639-645.
Pal PK, Thennarasu K, Fleming J, Schulzer M, Brown T, Calne SM. Nocturnal sleep disturbances and daytime dysfunction in patients with Parkinson’s disease and in their caregivers. Parkinsonism Relat Disord 2004;10:157-168.
Martinez-Martin P, Benito-Leon J, Alonso F, et al. Quality of life of caregivers in Parkinson’s disease. Qual Life Res 2005;14:463-472.
Cifu DX, Carne W, Brown R, et al. Caregiver distress in parkinsonism. J Rehabil Res Dev 2006;43:499-508.
Schrag A, Hovris A, Morley D, Quinn N, Jahanshahi M. Caregiver-burden in Parkinson’s disease is closely associated with psychiatric symptoms, falls, and disability. Parkinsonism Relat Disord 2006;12:35-41.
Schestatsky P, Zanatto VC, Margis R, et al. Quality of life in a Brazilian sample of patients with Parkinson’s disease and their caregivers. Rev Bras Psiquiatr 2006;28:209-211.
Aarsland D, Bronnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 2007;78:36.
Kim KS, Kim BJ, Kim KH, et al. Subjective and objective caregiver burden in Parkinson’s disease. Taehan Kanho Hakhoe Chi 2007;37:242-248.
Martinez-Martin P, Forjaz MJ, Frades-Payo B, et al. Caregiver burden in Parkinson’s disease. Mov Disord 2007a;22:924-931.
Carter JH, Stewart BJ, Lyons, KS, Archbold, PG. Do motor and nonmotor symptoms in PD patients predict caregiver strain and depression? Mov Disord 2008;23:1211-1216.
Lokk J. Caregiver strain in Parkinson’s disease and the impact of disease duration. Eur J Phys Rehabil Med 2008;44:39-45.
Martinez-Martin P, Arroyo S, Rojo-Abuin JM, Rodriguez-Blazquez C, Frades B, de Pedro CJ. Burden, perceived health status, and mood among caregivers of Parkinson’s disease patients. Mov Disord 2008;23:1673-1680.
D’Amelio M, Terruso V, Palmeri B, et al. Predictors of caregiver burden in partners of patients with Parkinson’s disease. Neurol Sci 2009;30:171-174.
Stella F, Banzato CE, Quagliato EM, Viana MA, Christofoletti G. Psychopathological features in patients with Parkinson’s disease and related caregivers’ burden. Int J Geriatr Psychiatry 2009;24:1158-1165.
Roland KP, Jenkins ME, Johnson AM. An exploration of the burden experienced by spousal caregivers of individuals with Parkinson’s disease. Mov Disord 2010;25:189-193.
Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992;30:473-483.
EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
WHO QOL Group. Development of the World Health Organization WHO QOL-BRE F quality of life assessment. Psychol Med 1998;28:551-558.
Glozman JM, Bicheva KG, Fedorova NV. Scale of quality of life of care-givers (SQLC). J Neurol 1998;245:39-41.
Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist 1980;20:649-655.
Novak M, Guest C. Application of a multidimensional caregiver burden inventory. The Gerontologist 1989;29:798-803.
Montgomery RJV, Gonyea JG, Hooyman NR. Caregiving and the experience of subjective and objective burden. Family Relations 1985;34:19-26.
Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology 2009;72(suppl 4):1-136.
Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology 1993;43:2227-2229.
Guttman M, Slaughter PM, Theriault ME, DeBoer DP, Naylor CD. Burden of parkinsonism: a population-based study. Mov Disord 2002;18:313-319.
Magerkurth C, Schnitzer R, Braune S. Symptoms of autonomic failure in Parkinson’s disease: prevalence and impact on daily life. Clin Autonom Res 2005;15:76-82.
Findley L, Aujla M, Bain PG, et al. Direct economic impact of Parkinson’s disease: a research survey in the United Kingdom. Mov Disord 2003;18:1139-1145.
Cubo E, Martinez-Martin P, Gonzalez M, Frades B, ELEP Group. Impact of motor and non-motor symptoms on the direct costs of Parkinson’s disease [Spanish]. Neurologia 2009;24:15-23.
Dodel RC, Singer M, Kohne-Volland R, et al. The economic impact of Parkinson’s disease: An estimation based on a 3-month prospective analysis. Pharmacoeconomics 1998;14:299-312.
Pålhagen S, Heinonen E, Hagglund J, Kaugesaar T, Maki-Ikola O, Palm R. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 2006;66:1200-1206.
Haycox A, Armand C, Murteira S, Cochran J, François C. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson’s disease in the UK setting: An economic Markov model evaluation. Drugs Aging 2009;26:791-801.
Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004;61:561-566.
Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 2009a;361:1268-1278.
Poewe W, Hauser R, Lang AE. Rasagiline 1 mg/day provides benefits in the progression of non-motor symptoms in patients with early Parkinson’s disease: Assessment with the revised MDS-UPDRS. Mov Disord 2009;24:S272-S273.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Healthcare, a part of Springer Science+Business Media
About this chapter
Cite this chapter
Forjaz, M.J., Chandiramani, C., Martinez-Martin, P. (2011). The Burden of Non-Motor Symptoms. In: Handbook of Non-Motor Symptoms in Parkinson's Disease. Springer Healthcare, Heidelberg. https://doi.org/10.1007/978-1-908517-60-9_2
Download citation
DOI: https://doi.org/10.1007/978-1-908517-60-9_2
Published:
Publisher Name: Springer Healthcare, Heidelberg
Print ISBN: 978-1-907673-23-8
Online ISBN: 978-1-908517-60-9
eBook Packages: MedicineMedicine (R0)